Drug intelligence / Profile preview

GDC-695

Development stage: Phase 3
Lead developer: Gage Development
Modality: Small Molecules
Administration: Topical

Overview

GDC-695 is a small molecule drug developed by Gage Development Company for the topical treatment of actinic keratosis, a precancerous skin condition. It has been formulated as a gel and was evaluated in clinical trials to compare its safety and efficacy against diclofenac sodium gel, 3%, which is an established therapy for actinic keratosis. The mechanism of action for GDC-695 remains undefined. Clinical development reached at least phase 3 trials, but there are no recent reports indicating further progress or approval[1][2][4][5].

Beyond the preview

Go deeper on GDC-695.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GDC-695.

Explore the full profile